Clinical and Experimental Allergy最新文献_第4页

KITY Study Protocol: A Randomised Controlled Trial for Eczema Prevention by Ingestion of Kestose in High-Risk Neonates. KITY研究方案：高危新生儿摄入酮糖预防湿疹的随机对照试验。

IF 6.3 2区医学 Q1 ALLERGY

Clinical and Experimental Allergy

Pub Date : 2024-12-18 DOI: 10.1111/cea.14612

Mayako Saito-Abe, Kenji Toyokuni, Hisako Ogasawara, Kyongsun Pak, Yusuke Inuzuka, Daisuke Harama, Nozomi Ando, Yutaka Koyano, Tohru Kobayashi, Yuka Hayashi, Hideaki Morita, Kenji Matsumoto, Tatsuki Fukuie, Yukihiro Ohya, Kiwako Yamamoto-Hanada

引用次数: 0

Impact of Co-Factors in Primary Hazelnut Allergy. 辅助因素对原发性榛子过敏的影响。

IF 6.3 2区医学 Q1 ALLERGY

Clinical and Experimental Allergy

Pub Date : 2024-12-18 DOI: 10.1111/cea.14611

Morten J Christensen, Annemarie Schaeffer Senders, Henrik Fomsgaard Kjaer, Carsten Bindslev-Jensen, Charlotte G Mortz

引用次数: 0

Detection and Characterisation of Wasp Venom-Specific T Cells Using the ARTE Method in Allergic Patients. 用ARTE方法检测和鉴定过敏患者的黄蜂毒液特异性T细胞。

IF 6.3 2区医学 Q1 ALLERGY

Clinical and Experimental Allergy

Pub Date : 2024-12-15 DOI: 10.1111/cea.14606

Magdalena Kraft, Samira Saleh, Guido Heine, Alexander Scheffold, Petra Bacher, Margitta Worm

引用次数: 0

Research Integrity in the Field of Atopic Dermatitis Treatment 特应性皮炎治疗领域的研究完整性。

IF 6.3 2区医学 Q1 ALLERGY

Clinical and Experimental Allergy

Pub Date : 2024-12-09 DOI: 10.1111/cea.14601

Robert J. Boyle, Mohamed H. Shamji

In this month's issue of Clinical and Experimental Allergy, we highlight the prize-winners from the recent highly successful BSACI conference and present a Cochrane systematic review of topical anti-inflammatory treatments for eczema (atopic dermatitis). Prize-winner abstracts reflected the breadth and depth of research presented at the BSACI conference, which continues to grow and will move to a new, larger venue next year. Please mark 16–18 October at the International Convention Centre in Newport, Wales in your diary! The Cochrane review findings are striking. Not so much for the findings on effectiveness and safety of topical eczema treatments, but for the lack of independence and transparency in the included clinical trials. Eczema is a common, burdensome condition—probably the most burdensome skin condition affecting humans—and topical anti-inflammatory treatments have been used for generations to manage eczema symptoms. In this first comprehensive Cochrane review of the topic, authors identified almost 400 randomised controlled trials in over 50,000 people with eczema. One might hope that such a significant human effort would have yielded some reliable information to guide clinician, carers and people with eczema in making treatment decisions. However, the standout finding in this review was the lack of transparency in the field (Figure 1). Risk of bias was judged to be high in 89% of trials, with the most common issue being concern about selective reporting. While older clinical trials would not be expected to register their plans on a public clinical trial registry or to make their protocol publicly available—it is of some concern that even the modern trials commonly lacked appropriate trial registration. Trial findings were also rarely reported completely, meaning that for many trials and outcomes, it was not possible to include data in meta-analysis. A common issue here was trialists not stating the number of participants evaluated for an outcome.This Cochrane review is a good example of the ways in which scientific progress, clinical practice and the health of relevant populations are held back when clinical trials are not conducted and reported in a transparent manner. It is relevant that only a tiny minority of these trials were funded independently—where stated, the funder was almost always the manufacturer of one of the topical treatments being tested. It is well-established that clinical trials funded in this way tend to report findings as more favourable, and in commercial trials, there are also obvious incentives for non-transparent reporting, unless this is legally mandated. While it is for the lawyers and regulators to legislate and oversee compliance with transparent reporting of clinical trials, journals also have a place in promoting better clinical trial practice. This is why Clinical & Experimental Allergy places great emphasis on transparency in reporting, especially for potentially influenti

在本月的《临床与实验变态反应》杂志上，我们重点介绍了最近非常成功的BSACI会议的获奖者，并发表了一篇关于局部抗炎治疗湿疹（特应性皮炎）的Cochrane系统综述。获奖者的摘要反映了在BSACI会议上展示的研究的广度和深度，该会议将继续发展，并将于明年搬到一个新的、更大的场地。请在您的日记中注明10月16日至18日在威尔士新港国际会议中心举行！Cochrane综述的发现是惊人的。不是因为局部湿疹治疗的有效性和安全性，而是因为在纳入的临床试验中缺乏独立性和透明度。湿疹是一种常见的、令人难以忍受的疾病——可能是影响人类的最令人难以忍受的皮肤疾病——几代人以来一直使用局部抗炎治疗来控制湿疹症状。在Cochrane对该主题的首次综合综述中，作者确定了近400项随机对照试验，涉及50,000多名湿疹患者。人们可能希望，如此重大的人类努力将产生一些可靠的信息，以指导临床医生，护理人员和湿疹患者做出治疗决定。然而，本综述的突出发现是该领域缺乏透明度（图1）。在89%的试验中，偏倚风险被认为是高的，最常见的问题是选择性报告。虽然老的临床试验不会被期望在公共临床试验登记处登记他们的计划或使他们的方案公开可用，但令人担忧的是，即使是现代试验也通常缺乏适当的试验注册。试验结果也很少被完整地报道，这意味着对于许多试验和结果，不可能将数据纳入荟萃分析。这里的一个常见问题是试验人员没有说明评估结果的参与者人数。这篇Cochrane综述是一个很好的例子，说明当临床试验没有以透明的方式进行和报告时，科学进步、临床实践和相关人群的健康都会受到阻碍。值得注意的是，这些试验中只有一小部分是独立资助的——在声明中，资助者几乎总是被测试的局部治疗之一的制造商。众所周知，以这种方式资助的临床试验往往会报告更有利的结果，而在商业试验中，也有明显的动机鼓励不透明的报告，除非法律强制要求这样做。虽然律师和监管机构有责任对临床试验的透明报告进行立法和监督，但期刊在促进更好的临床试验实践方面也有一席之地。这就是为什么Clinical &amp；实验过敏非常强调报告的透明度，特别是对于潜在的有影响力的手稿，如临床试验报告b[2]。我们发表研究方案和无效发现；我们鼓励作者公开所有相关材料——从试验前方案到统计分析计划、参与者信息表，以及在伦理可行的情况下，完整的临床试验数据集[3-7]。一个一直倡导提高临床试验报告透明度的慈善机构是Cochrane。我们定期在Clinical &amp；实验过敏。请与Parisut Kimkool [email protected]联系，如果你想写Cochrane Corner关于最近一篇与过敏领域相关的Cochrane综述。免疫学。在这一期，作者总结了最近Cochrane关于儿童胃食管反流的药物治疗的综述。这些治疗方法被广泛应用于儿童，包括增稠剂、促动力剂、H2拮抗剂和质子泵抑制剂。事实上，在婴儿中，有证据表明近年来这些产品的使用越来越多（图2）。在Cochrane综述的发现中有一个熟悉的模式。对于大多数纳入的试验，在公共领域没有可以提取的相关数据。即使对于那些可以提取数据的试验，试验设计和结果报告的异质性也意味着不能进行荟萃分析。部分原因是作者无法识别和分析涉及2251名儿童和成人的36项试验的相关结果，研究结果是不确定的——对所研究的干预措施的确定性证据非常低。作者得出结论，需要进一步的试验。然而，同样重要的是，这些未来的试验应该透明地报告，这样所有相关的临床试验数据都可以公开获得，以支持荟萃分析和循证决策。为了解决某些临床试验缺乏透明度和报告的问题，系统审稿人有时使用的一种方法是使用来自已确定试验的个体参与者数据（IPD）。这似乎确实提高了数据质量和系统评价结论的确定性。IPD荟萃分析耗时且昂贵，需要与临床试验团队达成数据共享协议并建立关系。然而，直到临床试验小组在法律上有义务公开他们的研究前计划和完整的试验数据集之前，IPD将在证据生态系统中占有重要地位。写了初稿。M.H.S.审阅并批准了手稿。通讯作者对本文负全部责任。作者声明无利益冲突。

{"title":"Research Integrity in the Field of Atopic Dermatitis Treatment","authors":"Robert J. Boyle, Mohamed H. Shamji","doi":"10.1111/cea.14601","DOIUrl":"10.1111/cea.14601","url":null,"abstract":"In this month's issue of Clinical and Experimental Allergy, we highlight the prize-winners from the recent highly successful BSACI conference and present a Cochrane systematic review of topical anti-inflammatory treatments for eczema (atopic dermatitis). Prize-winner abstracts reflected the breadth and depth of research presented at the BSACI conference, which continues to grow and will move to a new, larger venue next year. Please mark 16–18 October at the International Convention Centre in Newport, Wales in your diary! The Cochrane review findings are striking. Not so much for the findings on effectiveness and safety of topical eczema treatments, but for the lack of independence and transparency in the included clinical trials. Eczema is a common, burdensome condition—probably the most burdensome skin condition affecting humans—and topical anti-inflammatory treatments have been used for generations to manage eczema symptoms. In this first comprehensive Cochrane review of the topic, authors identified almost 400 randomised controlled trials in over 50,000 people with eczema. One might hope that such a significant human effort would have yielded some reliable information to guide clinician, carers and people with eczema in making treatment decisions. However, the standout finding in this review was the lack of transparency in the field (Figure 1). Risk of bias was judged to be high in 89% of trials, with the most common issue being concern about selective reporting. While older clinical trials would not be expected to register their plans on a public clinical trial registry or to make their protocol publicly available—it is of some concern that even the modern trials commonly lacked appropriate trial registration. Trial findings were also rarely reported completely, meaning that for many trials and outcomes, it was not possible to include data in meta-analysis. A common issue here was trialists not stating the number of participants evaluated for an outcome.This Cochrane review is a good example of the ways in which scientific progress, clinical practice and the health of relevant populations are held back when clinical trials are not conducted and reported in a transparent manner. It is relevant that only a tiny minority of these trials were funded independently—where stated, the funder was almost always the manufacturer of one of the topical treatments being tested. It is well-established that clinical trials funded in this way tend to report findings as more favourable, and in commercial trials, there are also obvious incentives for non-transparent reporting, unless this is legally mandated. While it is for the lawyers and regulators to legislate and oversee compliance with transparent reporting of clinical trials, journals also have a place in promoting better clinical trial practice. This is why Clinical & Experimental Allergy places great emphasis on transparency in reporting, especially for potentially influenti","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 12","pages":"950-952"},"PeriodicalIF":6.3,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14601","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Featured Cover 了封面

IF 6.3 2区医学 Q1 ALLERGY

Clinical and Experimental Allergy

Pub Date : 2024-12-09 DOI: 10.1111/cea.14609

Lichen Li, Dean J. Naisbitt, Yonghu Sun, Furen Zhang

The cover image is based on the article Pathomechanism of Adverse Reactions to Biological Treatment of Inflammatory Skin Conditions by Lichen Li et al., https://doi.org/10.1111/cea.14583.

封面图片来源于Lichen Li et al., https://doi.org/10.1111/cea.14583的文章《炎症性皮肤病生物治疗不良反应病理机制》。

引用次数: 0

Prize-Winning Abstracts From BSACI 2024 Meeting BSACI 2024年会议获奖摘要

IF 6.3 2区医学 Q1 ALLERGY

Clinical and Experimental Allergy

Pub Date : 2024-12-09 DOI: 10.1111/cea.14599

Mohamed H. Shamji, Robert J. Boyle

The annual British Society of Allergy and Clinical Immunology (BSACI) conference was held in Harrogate, York, UK, from 2 to 5 October 2024. This year, the Barry Kay Award, which recognises Professor Kay's national and international research contributions to the field of allergy and asthma which inspired so many young Allergists and Respiratory scientists, was awarded for the best abstracts in the Adult Clinical, Paediatric Clinical, Medical Student, Equality, Inclusivity and Diversity and Education categories. Here, we have asked the award recipients to summarise their research findings.Immunotherapy is a widely accepted treatment for allergic conditions, designed to alter the progression of the disease by promoting immune tolerance [1]. I presented a case of a person affected by severe allergic rhinitis, eczema, asthma and multiple food allergies. Investigations revealed Der p 23 sensitisation, indicating house dust mite allergy. Rhinitis symptoms failed to respond to multiple interventions, including biologics. However, addition of dust mite immunotherapy to biologic treatment resulted in significant symptom improvement. Der p 23, a minor HDM allergen, is not always present in high concentrations in commercially available immunotherapy extracts. Studies show that many HDM extracts from different manufacturers mainly contain Der p 1 and Der p 2, lacking Der p 23. However, other studies using mass spectrometry have shown a broader range of allergen representation, including Der p 23, in products from Allergy Therapeutics and ALK-Abelló A/S. The case underscores the importance of clinicians having a thorough understanding of the allergen content in immunotherapy products, as well as conducting specific allergen component assessments before initiating treatment. This ensures that immunotherapy is tailored to the patient's individual sensitization profile, enhancing its effectiveness.Educating parents on the recognition and management of allergic reactions is a central part of all paediatric allergy services [2, 3]. However, individual, in-person education has implications on resource management and consistency in delivery. Our institution utilises a two-part hybrid model comprising condensed in-person training followed by an online group webinar. We aimed to explore the parent experience of this model to inform our understanding of their information and education needs. The personal experiences of seven parents who completed the hybrid webinar education model were explored using one-on-one, semi-structured interviews, with an Interpretive Descriptive approach. These accounts were synthesised into three interpretive themes which described their perceived educational needs. Parents experienced significant barriers to learning during their clinic visit including cognitive overload, distractions and feeling overwhelmed. Multiple learning events facilitated addressing knowledge gaps and improved c

英国过敏与临床免疫学学会（BSACI）年度会议于2024年10月2日至5日在英国约克郡哈罗盖特举行。今年，Barry Kay奖授予了成人临床、儿科临床、医学生、平等、包容性和多样性以及教育类别的最佳摘要，该奖项表彰了Kay教授在过敏和哮喘领域的国家和国际研究贡献，激励了许多年轻的过敏症专家和呼吸系统科学家。在这里，我们请获奖者总结他们的研究成果。免疫疗法是一种被广泛接受的治疗过敏性疾病的方法，旨在通过促进免疫耐受来改变疾病的进展。我提出了一个病例，一个人的影响严重过敏性鼻炎，湿疹，哮喘和多种食物过敏。调查显示Der p23致敏，表明屋尘螨过敏。鼻炎症状对多种干预无效，包括生物制剂。然而，在生物治疗的基础上加入尘螨免疫治疗可显著改善症状。derp23是一种次要的HDM过敏原，在市售的免疫治疗提取物中并不总是高浓度存在。研究表明，许多不同厂家的HDM提取物主要含有Der p1和Der p2，缺乏Der p23。然而，其他使用质谱法的研究表明，过敏治疗公司和ALK-Abelló a /S公司的产品中含有更广泛的过敏原，包括Der p23。该病例强调了临床医生全面了解免疫治疗产品中过敏原含量的重要性，以及在开始治疗前进行特定过敏原成分评估的重要性。这确保了免疫疗法是量身定制的病人的个人致敏概况，提高其有效性。教育家长认识和管理过敏反应是所有儿科过敏服务的核心部分[2,3]。然而，个别的、面对面的教育对资源管理和交付的一致性有影响。我们的机构采用两部分混合模式，包括浓缩的面对面培训，然后是在线小组网络研讨会。我们的目的是探索这种模式的家长经验，以告知我们对他们的信息和教育需求的理解。本研究采用一对一、半结构化访谈的方式，采用解释性描述的方法，对完成混合网络研讨会教育模式的七位家长的个人经历进行了探讨。这些说法被综合成三个解释主题，描述了他们感知到的教育需求。家长们在诊所访问期间经历了重大的学习障碍，包括认知超载、分心和感到不知所措。多种学习活动有助于解决知识差距，提高信心和自我效能。远程学习有助于教育其他照料者，减轻照料者父母传播信息的负担。混合网络研讨会模式支持家长通过在首选的学习环境中重复、结构化的参与来学习。网上小组教育有助向其他护理人员传播知识和技能。制定同步和非同步教育战略的结合可以进一步支持家长的需要。牛奶过敏（CMA）影响约1%的婴儿，但由于其非特异性症状而难以诊断。牛奶相关症状评分（CoMiSS）是一种商业赞助的量化哭泣、反流、粪便变化、皮肤和呼吸问题的工具。得分≥10分提示婴儿CMA的可能性高。本研究利用EAT研究的症状问卷数据，评估CoMiSS诊断CMA的准确性。该研究涉及1295名3-12个月的健康母乳喂养婴儿，他们接受了盲法食物挑战和专家评估以确认CMA。在不知道婴儿CMA状态的情况下计算CoMiSS评分，并评估诊断表现。在1295例婴儿中，只有10例（0.8%）确诊为CMA，而CoMiSS鉴定492例（38.0%）为可能的CMA。对于每一个确诊的CMA病例，48个健康婴儿被标记为可能的CMA。CoMiSS敏感性为80.0%，特异性为62.3%，阳性预测值为1.6%，阴性预测值为99.8%。CoMiSS对IgE-CMA的敏感性为100%，但对非IgE-CMA的敏感性仅为50.0%，这可能是由于其对湿疹的重视。CoMiSS在识别CMA方面具有高灵敏度但低特异性，并且错误地将高比例的健康婴儿标记为可能患有CMA。CoMiSS是一种非特异性工具，特别是在检测非ige - cma时，诊断最具挑战性。斑贴试验（PT）有助于诊断非立即皮肤药物不良反应（NI-CADRs），但在英国过敏诊所很少进行。在我们的部门，我们建立了一个区域性的三级转诊中心，用于药物PT，在这里我们展示了英国最大的该患者队列研究。我们评估了2019年至2024年间在我们服务中进行贴片测试的ni - cadr患者；共117例患者接受了药物PT， NI-CADR和PT的中位时间间隔为12个月。总药物PT反应性为17.1%，22种不同药物检测出阳性结果。从表型上看，有嗜酸性粒细胞增多和全身症状的药物反应（DRESS）和急性全发性脓疱病（AGEP）的PT反应性最高（各为66.7%），其次是固定药疹（FDE）（33.3%）。PT反应性最高的是抗生素（68%）和碘造影剂（18%）。延迟皮内检测仅发现另外两例阳性病例（PT阴性）。没有患者出现全身再激活。PT诊断NI-CADR是一种安全有效的诊断工具，尤其适用于DRESS、AGEP、FDE、抗生素和碘造影剂。我们强调建立区域性三级药物过敏服务的好处。目的：通过伦敦中北部综合护理委员会的全科医生确定过敏服务患者的种族，特别是RLHIM，并将其与当地人口的种族数据进行比较，以调查任何可能的系统差异[5]。方法：从电子转诊服务（ERS）数据库中提取2023年4月1日至2024年3月31日期间NCL全科医生向过敏服务部门转诊的所有病例。从多个数据源获得患者和总体人口种族，使种族覆盖率超过95%。结果：在此期间发现了3133例过敏转诊，其中2194例（66%）是RLHIM，来自1,272,927人。种族百分比（RLHIM, Non-RLHIM， NCL人群）为：白人（51,54,56）；其他（14,14,15）；黑色（11,9,12）；亚洲（13,13,11），混合（5,3,4），未陈述（6,5,2）。NCL人群与过敏转诊样本（p = 0.65）或RLHIM样本（p = 0.4）之间没有统计学上的显著差异（Mann-Whitney U检验）。结论：对于这个样本，过敏服务的患者的种族，特别是RLHIM，似乎与当地人口相当匹配。长期暴露于环境空气污染与儿童bbb肺功能受损有关。天然气燃烧是尼日利亚南部尼日尔三角洲地区空气污染的一个重要原因。我们进行了一项横断面研究，涉及774名6-15岁的儿童（382名来自暴露于天然气燃烧的社区，392名来自未暴露于天然气燃烧的社区），以确定天然气燃烧对肺功能的影响。肺活量测定采用电子肺活量计。此外，使用手持式空气质量传感器测量臭氧（O3, ppm）、PM2.5和PM10 μg/m3 （PM10）。所有空气污染物（O3、PM2.5和PM10）在暴露人群中均显著高于未暴露人群（p = 0.03）。在暴露于天然气燃烧的社区中，所有肺活量z分数（FEV1 [- 1.68 vs. - 1.27]和FEV1/FVC [- 1.56 vs. - 0.28]）均显著降低（p均为0.001）。暴露于天然气燃烧的社区中，阻塞性表型的参与者比例明显高于非天然气燃烧社区（81人[21.2%]对22人[5.6%]）；P < 0.001)，在限制性表型上没有差异。总之，生活在一个暴露于天然气燃烧的社区与学龄期肺功能受损有关。

{"title":"Prize-Winning Abstracts From BSACI 2024 Meeting","authors":"Mohamed H. Shamji, Robert J. Boyle","doi":"10.1111/cea.14599","DOIUrl":"https://doi.org/10.1111/cea.14599","url":null,"abstract":"The annual British Society of Allergy and Clinical Immunology (BSACI) conference was held in Harrogate, York, UK, from 2 to 5 October 2024. This year, the Barry Kay Award, which recognises Professor Kay's national and international research contributions to the field of allergy and asthma which inspired so many young Allergists and Respiratory scientists, was awarded for the best abstracts in the Adult Clinical, Paediatric Clinical, Medical Student, Equality, Inclusivity and Diversity and Education categories. Here, we have asked the award recipients to summarise their research findings.Immunotherapy is a widely accepted treatment for allergic conditions, designed to alter the progression of the disease by promoting immune tolerance [1]. I presented a case of a person affected by severe allergic rhinitis, eczema, asthma and multiple food allergies. Investigations revealed Der p 23 sensitisation, indicating house dust mite allergy. Rhinitis symptoms failed to respond to multiple interventions, including biologics. However, addition of dust mite immunotherapy to biologic treatment resulted in significant symptom improvement. Der p 23, a minor HDM allergen, is not always present in high concentrations in commercially available immunotherapy extracts. Studies show that many HDM extracts from different manufacturers mainly contain Der p 1 and Der p 2, lacking Der p 23. However, other studies using mass spectrometry have shown a broader range of allergen representation, including Der p 23, in products from Allergy Therapeutics and ALK-Abelló A/S. The case underscores the importance of clinicians having a thorough understanding of the allergen content in immunotherapy products, as well as conducting specific allergen component assessments before initiating treatment. This ensures that immunotherapy is tailored to the patient's individual sensitization profile, enhancing its effectiveness.Educating parents on the recognition and management of allergic reactions is a central part of all paediatric allergy services [2, 3]. However, individual, in-person education has implications on resource management and consistency in delivery. Our institution utilises a two-part hybrid model comprising condensed in-person training followed by an online group webinar. We aimed to explore the parent experience of this model to inform our understanding of their information and education needs. The personal experiences of seven parents who completed the hybrid webinar education model were explored using one-on-one, semi-structured interviews, with an Interpretive Descriptive approach. These accounts were synthesised into three interpretive themes which described their perceived educational needs. Parents experienced significant barriers to learning during their clinic visit including cognitive overload, distractions and feeling overwhelmed. Multiple learning events facilitated addressing knowledge gaps and improved c","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 12","pages":"953-955"},"PeriodicalIF":6.3,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14599","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142860557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Food Allergy in Children in China. 中国儿童食物过敏

IF 6.3 2区医学 Q1 ALLERGY

Clinical and Experimental Allergy

Pub Date : 2024-12-06 DOI: 10.1111/cea.14596

Agnes Sze-Yin Leung, Shao Jie, Yanjun Gu, Gary Wing-Kin Wong

The prevalence of food allergies in China seems to be increasing, but there are limited studies describing the pattern of food allergies across the country. This review highlights regional variations observed across China, with data indicating a higher prevalence in the more economically developed eastern and southern coastal regions compared to inland areas. Egg and milk are the most common allergies among children under 3 years old; for children above 3 years old, specific food allergens also show regional differences, with shellfish allergies being more common in southern and eastern coastal areas, while wheat and fruit allergies are more prevalent in northern regions. Emerging peanut and tree nut allergies have also been observed in China's megacities, although the prevalence remains relatively low compared to Western countries. These geographic and environmental influences highlight the complexity of the food allergy landscape in China and the need for a more nuanced understanding of the underlying drivers. Despite the growing burden of food allergies, significant gaps exist in effectively managing these conditions in China. Lack of standardised diagnostic tools, limited access to oral food challenges and a shortage of trained allergists pose major challenges. Another critical gap is the limited availability and affordability of epinephrine autoinjectors, essential for managing life-threatening anaphylactic reactions. Addressing these systemic deficiencies in China's food allergy management infrastructure will require concerted efforts from policymakers, healthcare systems and pharmaceutical companies. Investing in the development of standardised diagnostics, expanding the allergy speciality workforce and ensuring equitable access to emergency care and treatment options are crucial steps towards improving health outcomes for the millions of individuals affected by food allergies in China.

中国食物过敏的患病率似乎在上升，但描述全国食物过敏模式的研究有限。这篇综述强调了在中国各地观察到的区域差异，数据表明，与内陆地区相比，经济发达的东部和南部沿海地区的患病率更高。鸡蛋和牛奶是3岁以下儿童最常见的过敏症；对于3岁以上的儿童，具体的食物过敏原也存在地区差异，南部和东部沿海地区贝类过敏更为常见，而北部地区小麦和水果过敏更为普遍。中国的大城市也出现了花生和树坚果过敏，尽管与西方国家相比，患病率仍相对较低。这些地理和环境影响突出了中国食物过敏状况的复杂性，以及对潜在驱动因素更细致入微的理解的必要性。尽管食物过敏的负担日益加重，但中国在有效管理这些疾病方面存在重大差距。缺乏标准化的诊断工具、获得口腔食物的机会有限以及缺乏训练有素的过敏症专家构成了重大挑战。另一个关键的缺口是肾上腺素自身注射器的有限供应和可负担性，而肾上腺素自身注射器对于治疗危及生命的过敏反应至关重要。解决中国食物过敏管理基础设施的这些系统性缺陷需要决策者、医疗保健系统和制药公司的共同努力。投资发展标准化诊断，扩大过敏专科队伍，确保公平获得紧急护理和治疗选择，是改善中国数百万食物过敏患者健康状况的关键步骤。

{"title":"Food Allergy in Children in China.","authors":"Agnes Sze-Yin Leung, Shao Jie, Yanjun Gu, Gary Wing-Kin Wong","doi":"10.1111/cea.14596","DOIUrl":"https://doi.org/10.1111/cea.14596","url":null,"abstract":"The prevalence of food allergies in China seems to be increasing, but there are limited studies describing the pattern of food allergies across the country. This review highlights regional variations observed across China, with data indicating a higher prevalence in the more economically developed eastern and southern coastal regions compared to inland areas. Egg and milk are the most common allergies among children under 3 years old; for children above 3 years old, specific food allergens also show regional differences, with shellfish allergies being more common in southern and eastern coastal areas, while wheat and fruit allergies are more prevalent in northern regions. Emerging peanut and tree nut allergies have also been observed in China's megacities, although the prevalence remains relatively low compared to Western countries. These geographic and environmental influences highlight the complexity of the food allergy landscape in China and the need for a more nuanced understanding of the underlying drivers. Despite the growing burden of food allergies, significant gaps exist in effectively managing these conditions in China. Lack of standardised diagnostic tools, limited access to oral food challenges and a shortage of trained allergists pose major challenges. Another critical gap is the limited availability and affordability of epinephrine autoinjectors, essential for managing life-threatening anaphylactic reactions. Addressing these systemic deficiencies in China's food allergy management infrastructure will require concerted efforts from policymakers, healthcare systems and pharmaceutical companies. Investing in the development of standardised diagnostics, expanding the allergy speciality workforce and ensuring equitable access to emergency care and treatment options are crucial steps towards improving health outcomes for the millions of individuals affected by food allergies in China.","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

One Year of Oral Immunotherapy Impacts the Gut Microbiota and Plasma Metabolome of Peanut-Allergic Young Children. 一年口服免疫疗法对花生过敏幼儿肠道微生物群和血浆代谢组的影响

IF 6.3 2区医学 Q1 ALLERGY

Clinical and Experimental Allergy

Pub Date : 2024-11-27 DOI: 10.1111/cea.14607

Isabella Badolati, Ymke de Jong, Carina Uhl, Josefin Ullberg, Marleen Joustra, Ulrika Lorentzon Fagerberg, Caroline Nilsson, Anna Asarnoj, Eva Sverremark-Ekström

引用次数: 0

Association of Abnormal Body Weight and Allergic Rhinitis-A Systematic Review and Meta-Analysis. 体重异常与过敏性鼻炎的关系--系统回顾与元分析。

IF 6.3 2区医学 Q1 ALLERGY

Clinical and Experimental Allergy

Pub Date : 2024-11-27 DOI: 10.1111/cea.14604

Brian Sheng Yep Yeo, Elaine Jiaxin Guan, Kaiwen Ng, Yun Sun Lim, Ryan Tsui Hon Goh, Xuandao Liu, Chu Qin Phua, Kaijun Tay, Lu Hui Png, Shuhui Xu, Neville Wei Yang Teo, Tze Choong Charn

Objective: Allergic rhinitis (AR) is a prevalent inflammatory condition of the nasal mucosa, with significant burden worldwide. While studies have demonstrated a relationship between body mass index (BMI) and other atopic diseases, its association with AR is uncertain. This study aims to clarify the association between non-normal BMI and AR.

Design: According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations, independent authors screened studies for eligibility, extracted data and assessed bias of included studies using the Newcastle-Ottawa scale and the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework. A random-effects meta-analysis was used to pool maximally covariate-adjusted estimates. Additional subgroup and bias analyses were performed.

Data sources: PubMed, Embase, Cochrane Library, SCOPUS and CINAHL were searched from inception to 14 January, 2024.

Eligibility criteria: Observational studies investigating the association between non-normal BMI and AR in both children and adults.

Results: We included 32 articles comprising 2,008,835 participants. The risk of bias was low (N = 20) or moderate (N = 12) and GRADE certainty of evidence was very low to low. Pooled cross-sectional analyses indicated that obese children (OR = 0.99, 95% CI = 0.96-1.03, I² = 0%), obese adults (OR = 1.11, 95% CI = 0.92-1.33, I² = 73%), overweight children (OR = 1.02, 95% CI = 0.98-1.06, I² = 35%), and overweight adults (OR = 1.13, 95% CI = 0.90-1.40, I² = 0%) showed similar odds of AR compared to controls. Additionally, longitudinal analyses did not identify any evidence for an association between overweight (OR = 1.03, 95% CI = 0.85-1.24, I² = 29%) or underweight (OR = 1.09, 95% CI = 0.77-1.54, I² = 72%) children and AR risk. These results remained largely robust across various subgroups and sensitivity assessments.

Conclusion: Abnormal BMI may not be associated with AR. This study adds to the expanding literature on the association between non-normal BMI and atopic diseases. Further prospective studies are needed to explore the longitudinal relationship between BMI and AR and the effect of weight loss interventions on AR, given the limits of existing literature.

Trial registration: PROSPERO CRD42024503589.

目的：过敏性鼻炎（AR）是一种普遍存在的鼻粘膜炎症，在全球范围内造成了巨大的负担。研究表明，体重指数（BMI）与其他特应性疾病之间存在关系，但其与过敏性鼻炎之间的关系尚不确定。本研究旨在阐明非正常体重指数与 AR 之间的关系：根据系统综述和荟萃分析首选报告项目（PRISMA）建议，独立作者筛选了符合条件的研究，提取了数据，并使用纽卡斯尔-渥太华量表和推荐、评估、发展和评价分级（GRADE）框架评估了纳入研究的偏倚性。随机效应荟萃分析用于汇集最大协变量调整估计值。另外还进行了亚组和偏倚分析：对 PubMed、Embase、Cochrane Library、SCOPUS 和 CINAHL 进行了检索，检索时间从开始到 2024 年 1 月 14 日：调查儿童和成人非正常体重指数与 AR 之间关系的观察性研究：我们纳入了 32 篇文章，共有 2,008,835 名参与者。偏倚风险为低（20 篇）或中度（12 篇），GRADE 证据确定性为极低至低。汇总的横断面分析表明，与对照组相比，肥胖儿童（OR = 0.99，95% CI = 0.96-1.03，I2 = 0%）、肥胖成人（OR = 1.11，95% CI = 0.92-1.33，I2 = 73%）、超重儿童（OR = 1.02，95% CI = 0.98-1.06，I2 = 35%）和超重成人（OR = 1.13，95% CI = 0.90-1.40，I2 = 0%）出现 AR 的几率相似。此外，纵向分析没有发现任何证据表明超重（OR = 1.03，95% CI = 0.85-1.24，I2 = 29%）或体重不足（OR = 1.09，95% CI = 0.77-1.54，I2 = 72%）儿童与 AR 风险之间存在关联。这些结果在不同的亚组和敏感性评估中基本保持稳定：结论：BMI异常可能与AR无关。这项研究补充了有关非正常体重指数与特应性疾病之间关系的文献。鉴于现有文献的局限性，需要进一步开展前瞻性研究，探讨体重指数与特应性红细胞增多症之间的纵向关系，以及减肥干预措施对特应性红细胞增多症的影响：试验注册：PREMCO CRD42024503589。

{"title":"Association of Abnormal Body Weight and Allergic Rhinitis-A Systematic Review and Meta-Analysis.","authors":"Brian Sheng Yep Yeo, Elaine Jiaxin Guan, Kaiwen Ng, Yun Sun Lim, Ryan Tsui Hon Goh, Xuandao Liu, Chu Qin Phua, Kaijun Tay, Lu Hui Png, Shuhui Xu, Neville Wei Yang Teo, Tze Choong Charn","doi":"10.1111/cea.14604","DOIUrl":"https://doi.org/10.1111/cea.14604","url":null,"abstract":"Objective: Allergic rhinitis (AR) is a prevalent inflammatory condition of the nasal mucosa, with significant burden worldwide. While studies have demonstrated a relationship between body mass index (BMI) and other atopic diseases, its association with AR is uncertain. This study aims to clarify the association between non-normal BMI and AR.Design: According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations, independent authors screened studies for eligibility, extracted data and assessed bias of included studies using the Newcastle-Ottawa scale and the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework. A random-effects meta-analysis was used to pool maximally covariate-adjusted estimates. Additional subgroup and bias analyses were performed.Data sources: PubMed, Embase, Cochrane Library, SCOPUS and CINAHL were searched from inception to 14 January, 2024.Eligibility criteria: Observational studies investigating the association between non-normal BMI and AR in both children and adults.Results: We included 32 articles comprising 2,008,835 participants. The risk of bias was low (N = 20) or moderate (N = 12) and GRADE certainty of evidence was very low to low. Pooled cross-sectional analyses indicated that obese children (OR = 0.99, 95% CI = 0.96-1.03, I2 = 0%), obese adults (OR = 1.11, 95% CI = 0.92-1.33, I2 = 73%), overweight children (OR = 1.02, 95% CI = 0.98-1.06, I2 = 35%), and overweight adults (OR = 1.13, 95% CI = 0.90-1.40, I2 = 0%) showed similar odds of AR compared to controls. Additionally, longitudinal analyses did not identify any evidence for an association between overweight (OR = 1.03, 95% CI = 0.85-1.24, I2 = 29%) or underweight (OR = 1.09, 95% CI = 0.77-1.54, I2 = 72%) children and AR risk. These results remained largely robust across various subgroups and sensitivity assessments.Conclusion: Abnormal BMI may not be associated with AR. This study adds to the expanding literature on the association between non-normal BMI and atopic diseases. Further prospective studies are needed to explore the longitudinal relationship between BMI and AR and the effect of weight loss interventions on AR, given the limits of existing literature.Trial registration: PROSPERO CRD42024503589.","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142738650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Caesarean Section and Atopic Dermatitis Risk: Insights From a Nationwide, Population-Based Cohort Study. 剖腹产与特应性皮炎风险：一项基于全国人口的队列研究的启示。

IF 6.3 2区医学 Q1 ALLERGY

Clinical and Experimental Allergy

Pub Date : 2024-11-26 DOI: 10.1111/cea.14603

Po-Han Chen, Dereck Shen, Tom C Chan, Yung-Tsu Cho, Chao-Hsiun Tang, Chia-Yu Chu

引用次数: 0